Sientra (SIENQ) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 05, 2021
Cover [Abstract]
Entity Registrant Name	SIENTRA, INC.
Entity Central Index Key	0001551693
Document Type	10-Q
Document Period End Date	Sep. 30, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		58,122,465
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Trading Symbol	SIEN
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-36709
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-5551000
Entity Address, Address Line One	420 South Fairview Avenue
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Santa Barbara
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	93117
City Area Code	805
Local Phone Number	562-3500
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 66,127	$ 54,967
Accounts receivable, net of allowances of $1,833 and $1,047 at September 30, 2021 and December 31, 2020, respectively	26,453	19,771
Inventories, net	51,529	39,168
Prepaid expenses and other current assets	2,663	1,891
Current assets of discontinued operations	4	13,475
Total current assets	146,776	129,272
Property and equipment, net	14,886	12,301
Goodwill	9,202	9,202
Other intangible assets, net	8,471	9,387
Other assets	7,323	8,011
Non-current assets of discontinued operations		805
Total assets	186,658	168,978
Current liabilities:
Current portion of long-term debt		4,670
Accounts payable	6,300	5,799
Accrued and other current liabilities	22,285	28,408
Customer deposits	30,286	17,905
Sales return liability	12,305	9,192
Current liabilities of discontinued operations	501	4,686
Total current liabilities	71,677	70,660
Long-term debt	61,483	60,500
Derivative liability		26,570
Deferred and contingent consideration	2,786	2,350
Warranty reserve and other long-term liabilities	9,950	9,455
Total liabilities	145,896	169,535
Commitments and contingencies (Note 12)
Stockholders’ equity (deficit):
Preferred stock, $0.01 par value – Authorized 10,000,000 shares; none issued or outstanding
Common stock, $0.01 par value — Authorized 200,000,000 shares; issued 58,129,589 and 50,712,151 and outstanding 58,056,862 and 50,639,424 shares at September 30, 2021 and December 31, 2020, respectively	581	506
Additional paid-in capital	645,717	558,059
Treasury stock, at cost (72,727 shares at September 30, 2021 and December 31, 2020)	(260)	(260)
Accumulated deficit	(605,276)	(558,862)
Total stockholders’ equity (deficit)	40,762	(557)
Total liabilities and stockholders’ equity	$ 186,658	$ 168,978

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Accounts receivable, allowances (in dollars)	$ 1,833	$ 1,047
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	58,129,589	50,712,151
Common stock, shares outstanding	58,056,862	50,639,424
Treasury stock, shares	72,727	72,727

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Net sales	$ 19,620,000	$ 15,329,000	$ 58,035,000	$ 37,109,000
Cost of goods sold	9,030,000	7,105,000	26,027,000	15,887,000
Gross profit	10,590,000	8,224,000	32,008,000	21,222,000
Operating expenses:
Sales and marketing	12,052,000	9,969,000	34,348,000	24,858,000
Research and development	2,367,000	1,778,000	6,962,000	6,142,000
General and administrative	7,865,000	6,445,000	23,321,000	21,183,000
Restructuring		(442,000)		389,000
Total operating expenses	22,284,000	17,750,000	64,631,000	52,572,000
Loss from operations	(11,694,000)	(9,526,000)	(32,623,000)	(31,350,000)
Other income (expense), net:
Interest income	1,000	6,000	4,000	203,000
Interest expense	(2,026,000)	(2,055,000)	(6,143,000)	(7,284,000)
Change in fair value of derivative liability	35,550,000	10,090,000	(14,460,000)	(8,420,000)
Other income (expense), net	6,672,000	(2,000)	6,575,000	34,000
Total other income (expense), net	40,197,000	8,039,000	(14,024,000)	(15,467,000)
Income (loss) from continuing operations before income taxes	28,503,000	(1,487,000)	(46,647,000)	(46,817,000)
Income tax expense (benefit)	0	0	0	0
Income (loss) from continuing operations	28,503,000	(1,487,000)	(46,647,000)	(46,817,000)
Income (loss) from discontinued operations, net of income taxes	(93,000)	(4,334,000)	233,000	(21,893,000)
Net income (loss)	$ 28,410,000	$ (5,821,000)	$ (46,414,000)	$ (68,710,000)
Basic earnings (loss) per share:
Continuing operations	$ 0.49	$ (0.03)	$ (0.82)	$ (0.93)
Discontinued operations	0	(0.09)	0	(0.44)
Basic earnings (loss) per share	0.49	(0.12)	(0.82)	(1.37)
Diluted earnings (loss) per share:
Continuing operations	(0.08)	(0.03)	(0.82)	(0.93)
Discontinued operations	0	(0.09)	0	(0.44)
Diluted earnings (loss) per share	$ (0.08)	$ (0.12)	$ (0.82)	$ (1.37)
Weighted average outstanding common shares used for net income (loss) per share attributable to common stockholders:
Basic	58,005,784	50,394,858	56,680,594	50,155,623
Diluted	72,639,930	50,394,858	56,680,594	50,155,623

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Follow-on Offering	ATM	Common stock	Common stockFollow-on Offering	Common stockATM	Treasury stock	Additional paid-in capital	Additional paid-in capitalFollow-on Offering	Additional paid-in capitalATM	Accumulated deficit
Balance, beginning of year at Dec. 31, 2019	$ 81,882			$ 495			$ (260)	$ 550,562			$ (468,915)
Balance, beginning of year (in shares) at Dec. 31, 2019				49,612,907			72,727
Issuance of/proceeds from common stock			$ 264			$ 1				$ 263
Issuance of/proceeds from common stock (in shares)						37,000
Stock-based compensation	2,000							2,000
Employee stock purchase program (ESPP)	534			$ 1				533
Employee stock purchase program (ESPP) (in shares)				113,615
Vested restricted stock				$ 5				(5)
Vested restricted stock (in shares)				472,914
Shares withheld for tax obligations on vested RSUs	(1,201)			$ (2)				(1,199)
Shares withheld for tax obligations on vested RSUs, shares				(157,412)
Net loss	(28,612)										(28,612)
Balance, end of year at Mar. 31, 2020	54,867			$ 500			$ (260)	552,154			(497,527)
Balance, end of year (in shares) at Mar. 31, 2020				50,079,024			72,727
Balance, beginning of year at Dec. 31, 2019	81,882			$ 495			$ (260)	550,562			(468,915)
Balance, beginning of year (in shares) at Dec. 31, 2019				49,612,907			72,727
Net loss	(68,710)
Balance, end of year at Sep. 30, 2020	18,084			$ 504			$ (260)	555,465			(537,625)
Balance, end of year (in shares) at Sep. 30, 2020				50,507,635			72,727
Balance, beginning of year at Mar. 31, 2020	54,867			$ 500			$ (260)	552,154			(497,527)
Balance, beginning of year (in shares) at Mar. 31, 2020				50,079,024			72,727
Stock-based compensation	1,718							1,718
Stock option exercises	13							13
Stock option exercises (in shares)				5,454
Employee stock purchase program (ESPP)	(5)							(5)
Employee stock purchase program (ESPP) (in shares)				(1,012)
Vested restricted stock				$ 4				(4)
Vested restricted stock (in shares)				363,795
Shares withheld for tax obligations on vested RSUs	(227)			$ (1)				(226)
Shares withheld for tax obligations on vested RSUs, shares				(91,529)
Net loss	(34,277)										(34,277)
Balance, end of year at Jun. 30, 2020	22,089			$ 503			$ (260)	553,650			(531,804)
Balance, end of year (in shares) at Jun. 30, 2020				50,355,732			72,727
Stock-based compensation	1,574							1,574
Stock option exercises	3							3
Stock option exercises (in shares)				727
Employee stock purchase program (ESPP)	307			$ 1				306
Employee stock purchase program (ESPP) (in shares)				91,125
Vested restricted stock				$ 1				(1)
Vested restricted stock (in shares)				85,255
Shares withheld for tax obligations on vested RSUs	(68)			$ (1)				(67)
Shares withheld for tax obligations on vested RSUs, shares				(25,204)
Net loss	(5,821)										(5,821)
Balance, end of year at Sep. 30, 2020	18,084			$ 504			$ (260)	555,465			(537,625)
Balance, end of year (in shares) at Sep. 30, 2020				50,507,635			72,727
Balance, beginning of year at Dec. 31, 2020	(557)			$ 506			$ (260)	558,059			(558,862)
Balance, beginning of year (in shares) at Dec. 31, 2020				50,712,151			72,727
Issuance of/proceeds from common stock		$ 39,226			$ 62				$ 39,164
Issuance of/proceeds from common stock (in shares)					6,222,222
Stock-based compensation	3,163							3,163
Stock option exercises	51							51
Stock option exercises (in shares)				12,727
Employee stock purchase program (ESPP)	323			$ 1				322
Employee stock purchase program (ESPP) (in shares)				95,919
Vested restricted stock	758			$ 6				752
Vested restricted stock (in shares)				554,896
Shares withheld for tax obligations on vested RSUs	(1,215)			$ (1)				(1,214)
Shares withheld for tax obligations on vested RSUs, shares				(82,830)
Net loss	(54,690)										(54,690)
Balance, end of year at Mar. 31, 2021	(12,941)			$ 574			$ (260)	600,297			(613,552)
Balance, end of year (in shares) at Mar. 31, 2021				57,515,085			72,727
Balance, beginning of year at Dec. 31, 2020	(557)			$ 506			$ (260)	558,059			(558,862)
Balance, beginning of year (in shares) at Dec. 31, 2020				50,712,151			72,727
Net loss	(46,414)
Balance, end of year at Sep. 30, 2021	40,762			$ 581			$ (260)	645,717			(605,276)
Balance, end of year (in shares) at Sep. 30, 2021				58,129,589			72,727
Balance, beginning of year at Mar. 31, 2021	(12,941)			$ 574			$ (260)	600,297			(613,552)
Balance, beginning of year (in shares) at Mar. 31, 2021				57,515,085			72,727
Stock-based compensation	2,584							2,584
Stock option exercises	95			$ 1				94
Stock option exercises (in shares)				23,636
Vested restricted stock	247			$ 5				242
Vested restricted stock (in shares)				471,759
Shares withheld for tax obligations on vested RSUs	(727)			$ (1)				(726)
Shares withheld for tax obligations on vested RSUs, shares				(81,386)
Net loss	(20,134)										(20,134)
Balance, end of year at Jun. 30, 2021	(30,876)			$ 579			$ (260)	602,491			(633,686)
Balance, end of year (in shares) at Jun. 30, 2021				57,929,094			72,727
Stock-based compensation	2,326							2,326
Employee stock purchase program (ESPP)	350			$ 1				349
Employee stock purchase program (ESPP) (in shares)				103,152
Vested restricted stock				$ 1				(1)
Vested restricted stock (in shares)				148,098
Shares withheld for tax obligations on vested RSUs	(478)							(478)
Shares withheld for tax obligations on vested RSUs, shares				(50,755)
Reclassification of derivative liability to equity	41,030							41,030
Net loss	28,410										28,410
Balance, end of year at Sep. 30, 2021	$ 40,762			$ 581			$ (260)	$ 645,717			$ (605,276)
Balance, end of year (in shares) at Sep. 30, 2021				58,129,589			72,727

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (46,414)	$ (68,710)
Income (loss) from discontinued operations, net of income taxes	233	(21,893)
Loss from continuing operations, net of income taxes	(46,647)	(46,817)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	3,149	2,386
Provision for doubtful accounts	875	258
Provision for warranties	684	362
Provision for inventory	638	1,435
Fair value adjustments to derivative liability	14,460	8,420
Fair value adjustments of other liabilities held at fair value	49	29
Amortization of debt discount and issuance costs	2,632	3,430
Gain on extinguishment of debt	(6,652)
Stock-based compensation expense	8,073	5,342
Payments of contingent consideration liability in excess of acquisition-date fair value	(2,419)
Other non-cash adjustments	584	198
Changes in operating assets and liabilities:
Accounts receivable	(7,558)	(5,311)
Inventories	(12,999)	(6,569)
Prepaid expenses, other current assets and other assets	(205)	(166)
Accounts payable, accrueds, and other liabilities	1,279	(4,921)
Customer deposits	12,381	1,547
Sales return liability	3,113	1,930
Net cash flow from operating activities - continuing operations	(28,563)	(38,447)
Net cash flow from operating activities - discontinued operations	(989)	(14,292)
Net cash used in operating activities	(29,552)	(52,739)
Cash flows from investing activities:
Purchase of property and equipment	(4,882)	(3,112)
Net cash flow from investing activities - continuing operations	(4,882)	(3,112)
Net cash flow from investing activities - discontinued operations	11,314	(80)
Net cash provided by (used in) investing activities	6,432	(3,192)
Cash flows from financing activities:
Proceeds from issuance of common stock for employee stock-based plans	1,824	852
Net proceeds from issuance of common stock	39,226	264
Tax payments related to shares withheld for vested restricted stock units (RSUs)	(2,420)	(1,496)
Gross borrowings under the Term Loan	1,000
Repayments under the Term Loan		(25,000)
Repayment of the Revolving Loan		(6,508)
Net proceeds from issuance of the Convertible Note		60,000
Payments of contingent consideration up to acquisition-date fair value	(4,550)
Deferred financing costs	(800)	(2,958)
Net cash provided by financing activities	34,280	31,806
Net increase (decrease) in cash, cash equivalents and restricted cash	11,160	(24,125)
Cash, cash equivalents and restricted cash at:
Beginning of period	55,300	87,951
End of period	66,460	63,826
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents	66,127	63,483
Restricted cash included in other assets	$ 333	$ 343
Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
End of period	$ 66,460	$ 63,826
Supplemental disclosure of cash flow information:
Interest paid	3,133	3,781
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment in accounts payable and accrued liabilities	323	114
Equity component of the Convertible Note	$ 41,030
Paycheck Protection Program
Cash flows from financing activities:
Gross borrowings under the PPP Loan		$ 6,652

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1 . a. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Sientra, Inc. (“Sientra”, the “Company”, “we”, “our”, or “us”) in this Quarterly Report on Form 10-Q have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and the rules and regulations of the U.S. Securities and Exchange Commission, or SEC. Accordingly, they do not include certain footnotes and financial presentations normally required under accounting principles generally accepted in the United States of America for complete financial reporting. The interim financial information is unaudited, but reflects all normal adjustments and accruals which are, in the opinion of management, considered necessary to provide a fair presentation for the interim periods presented. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 11, 2021, or the Annual Report. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period. As a result of the miraDry Sale discussed in Note 2, the miraDry business met the criteria to be reported as discontinued operations. Therefore, the Company is reporting the historical results of miraDry, including the results of operations, cash flows, and related assets and liabilities, as discontinued operations for all periods presented herein through the date of the Sale. Unless otherwise noted, the accompanying notes to the unaudited condensed consolidated financial statements have all been revised to reflect continuing operations only. As discussed in Note 11, following the Sale the Company has one operating segment in continuing operations named Plastic Surgery, formerly known as Breast Products. b. Liquidity Since the Company’s inception, it has incurred significant net operating losses and the Company anticipates that losses will continue in the near term. The Company expects its operating expenses will remain consistent with the current period and will need to generate significant net sales to achieve profitability. To date, the Company has funded operations primarily with proceeds from the sales of preferred stock, borrowings under term loans and the convertible note, sales of products since 2012, and the proceeds from the sale of common stock in public offerings. To fund ongoing operating and capital needs, the Company may need to raise additional capital in the future through the sale of equity securities and incremental debt financing. Sale of the miraDry business Refer to Note 2 for details on the sale of the miraDry business. Debt financing – recent developments Refer to Note 7 for a full description and updates to all of the Company’s long-term debt, revolving line of credit, convertible note, and Paycheck Protection Program (PPP) loan. Equity financing – recent developments On February 8, 2021, the Company completed a follow-on public offering of 5,410,628 shares of common stock at $6.75 per share, as well as 811,594 additional shares of common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. Net proceeds were approximately $39.2 million after deducting underwriting discounts and commissions of approximately $2.5 million and offering expenses of approximately $0.3 million . As of September 30, 2021, the Company had cash and cash equivalents of $66.1 million. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company believes that its cash and cash equivalents will be sufficient to fund its operations for at least the next 12 months. c. Recent Accounting Pronouncements Recently Adopted Accounting Standards In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes d. Risks and Uncertainties As an aesthetics company, surgical procedures involving the Company’s breast products are susceptible to local and national government restrictions, such as social distancing, vaccination requirements, “shelter in place” orders and business closures. The inability or limited ability to perform such non-emergency procedures significantly harmed the Company’s revenues since the second quarter of 2020 and continued to harm the Company’s revenues during the nine months ended September 30, 2021. While many states have lifted certain restrictions on non-emergency procedures, the Company will likely continue to experience future harm to its revenues while existing or new restrictions remain in place. It is not possible to accurately predict the length or severity of the COVID-19 pandemic or the timing for a broad and sustained ability to perform non-emergency procedures involving the Company’s products. The Company continues to monitor and assess new information related to the COVID-19 pandemic, the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. Further, the spread of COVID-19 has caused the Company to modify workforce practices, and the Company may take further actions determined to be in the best interests of the Company’s employees or as required by governments. The continued spread of COVID-19, or another infectious disease, could also result in delays or disruptions in the Company’s supply chain or adversely affect the Company’s manufacturing facilities and personnel. Further, trade and/or national security protection policies may be adjusted as a result of the COVID-19 pandemic, such as actions by governments that limit, restrict or prevent the movement of certain goods into a country and/or region, and current U.S./China trade relations may be further exacerbated by the pandemic. The estimates used for, but not limited to, determining the collectability of accounts receivable, fair value of long-lived assets and goodwill, and sales returns liability required could be impacted by the pandemic. While the full impact of COVID-19 is unknown at this time, the Company has made appropriate estimates based on the facts and circumstances available as of the reporting date. These estimates may change as new events occur and additional information is obtained. e. Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2021
Discontinued Operations And Disposal Groups [Abstract]
Discontinued Operations	2 . Discontinued Operations On June 10, 2021, the Company completed the sale of its miraDry business (the “Sale”) to miraDry Acquisition Company, Inc., a Delaware corporation (“Buyer”), an entity affiliated with 1315 Capital II, LP, as a result of the Company’s strategic decision to focus investment on its core Plastic Surgery segment. The Sale was made pursuant to the terms and conditions of the Asset Purchase Agreement (the “Purchase Agreement”), dated May 11, 2021, among the Company and certain of its subsidiaries, Buyer, and, solely for purposes of Section 8.14 of the Purchase Agreement, 1315 Capital II, LP. The aggregate purchase price was $10.0 million, which after certain adjustments for agreed upon changes in the estimated net asset value amount of purchased assets and assumed liabilities resulted in net cash proceeds of $11.3 million to the Company on the date of close. As of September 30, 2021, the Company has an escrow liability of $3.2 million in “Accrued and other current liabilities” on the condensed consolidated balance sheet to account for additional agreed upon post close changes in the net asset value and has recognized a loss on sale of $2.5 million. In October 2021, the Company finalized the transaction and paid $3.2 million to the Buyer in accordance with the agreed upon post close changes in the net asset value. In accordance with the Purchase Agreement, assumed liabilities did not include product liabilities, environmental, and employee claims arising prior to the closing date. The Purchase Agreement also included customary representations and warranties, as well as certain covenants, including, among other things, that: (i) the Company will abide by certain non-solicitation, exclusivity, and non-competition covenants, and (ii) the Company would enter into a transition services agreement (“TSA”) to provide certain transition services related to the business. Under the TSA, the Company provides certain post-closing services to the Buyer related to the miraDry business for a period of up to six months, including accounting, accounts receivable support, customer service, IT, regulatory, quality assurance, and clinical support. As consideration for these services, the Buyer will reimburse the Company for direct and certain indirect costs, as well as certain overhead or administrative expenses related to operating the business. The Company recognized $0.1 million of TSA fees and cost reimbursements in operating expenses from continuing operations in the condensed consolidated statement of operations for the nine months ended September 30, 2021. As of September 30, 2021, the Company has received $0.3 million relating to the TSA services and has recorded a receivable of $0.1 million within other current assets in the condensed consolidated balance sheets. In connection with the accounts receivable support under the TSA, the Company received $2.3 million in customer payments and remitted $2.2 million to the Buyer during the period from June 10, 2021 through September 30, 2021. As of September 30, 2021, the Company has recorded a $0.1 million payable in accounts payable on the condensed consolidated balance sheets. Additionally, the Company and the Buyer entered into a sublease agreement whereby the Buyer will sublease the miraDry office space in Santa Clara, CA. The sublease term is for an initial period of six months, with subsequent option periods for up to a total of twenty four months. During the three and nine months ended September 30, 2021, the Company recognized $0.2 million and $0.3 million, respectively, of sublease income in general and administrative expenses in the condensed consolidated statements of operations. The Sale met the discontinued operations criteria given that the business is a component and represented a strategic shift. The following table presents the aggregate carrying amount s of major classes of assets and liabilities of discontinued operations (in thousands): September 30, December 31, 2021 2020 Assets of discontinued operations: Accounts receivable, net $ — $ 3,732 Inventories, net — 9,480 Prepaid expenses and other current assets 4 263 Current assets of discontinued operations 4 13,475 Property and equipment, net — 805 Total assets of discontinued operations $ 4 $ 14,280 Liabilities of discontinued operations: Accounts payable $ 6 $ 704 Accrued and other current liabilities 495 3,982 Total liabilities of discontinued operations $ 501 $ 4,686 The results of operations for the miraDry business were included in income (loss) from discontinued operations on the accompanying condensed consolidated statements of operations. The following table provides information regarding the results of discontinued operations (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Net sales $ — $ 3,888 $ 9,347 $ 11,488 Cost of goods sold — 1,286 4,805 4,846 Gross profit — 2,602 4,542 6,642 Operating expenses 57 7,034 1,744 28,571 Income (loss) from operations of discontinued operations (57 ) (4,432 ) 2,798 (21,929 ) Other income (expense), net — 98 (77 ) 36 Income (loss) from discontinued operations before income taxes (57 ) (4,334 ) 2,721 (21,893 ) Loss on sale of discontinued operations before income taxes (36 ) — (2,488 ) — Total income (loss) from discontinued operations before income taxes (93 ) (4,334 ) 233 (21,893 ) Income tax expense (benefit) — — — — Income (loss) from discontinued operations, net of income taxes $ (93 ) $ (4,334 ) $ 233 $ (21,893 ) The results of the miraDry business, including the results of operations, cashflows, and related assets and liabilities are reported as discontinued operations for all periods presented herein.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2021
Revenue From Contract With Customer [Abstract]
Revenue	3 . Revenue The Company generates revenue primarily through the sale and delivery of promised goods or services to customers. Sales prices are documented in the executed sales contract, purchase order or order acknowledgement prior to the transfer of control to the customer. Typical payment terms are 30 days. Revenue contracts may include multiple products or services, each of which is considered a separate performance obligation. Performance obligations typically include the delivery of promised products, such as breast implants, tissue expanders, and BIOCORNEUM, along with service-type warranties. Other deliverables are sometimes promised but are ancillary and insignificant in the context of the contract as a whole . Revenue is allocated to each performance obligation based on its relative standalone selling price. The Company determines standalone selling prices based on observable prices for all performance obligations with the exception of the service-type warranty under the Platinum20 Limited Warranty Program, or Platinum20 , which is based on the expected cost plus margin approach. Inputs into the expected cost plus margin approach include historical incidence rates, estimated replacement costs, estimated financial assistance payouts and an estimated margin. The liability for unsatisfied performance obligations under the service warranty as of September 30, 2021 were as follows: Nine Months Ended September 30, 2021 Balance as of December 31, 2020 $ 1,945 Additions and adjustments 1,379 Revenue recognized (411 ) Balance as of September 30, 2021 $ 2,913 Revenue for service warranties are recognized ratably over the term of the agreements. Specifically for Platinum20, the performance obligation is satisfied at the time that the benefits are provided and are expected to be satisfied over the following 3 to 24 month period for financial assistance and 20 years for product replacement. For delivery of promised products, control transfers and revenue is recognized upon shipment, unless the contractual arrangement requires transfer of control when products reach their destination, for which revenue is recognized once the product arrives at its destination. A portion of the Company’s revenue is generated from the sale of consigned inventory of breast implants and tissue expanders maintained at doctor, hospital, and clinic locations. For these products, revenue is recognized at the time the Company is notified by the customer that the product has been used, not when the consigned products are delivered to the customer’s location. Sales Return Liability With the exception of the Company’s BIOCORNEUM scar management products, the Company allows for the return of products from customers within six months after the original sale, which is accounted for as variable consideration. A sales return liability is established based on estimated returns using relevant historical experience taking into consideration recent gross sales and notifications of pending returns, as adjusted for changes in recent industry events and trends. The estimated sales returns are recorded as a reduction of revenue and as a sales return liability in the same period revenue is recognized. Actual sales returns in any future period are inherently uncertain and thus may differ from the estimates. If actual sales returns differ significantly from the estimates, an adjustment to revenue in the current or subsequent period would be recorded. The following table provides a rollforward of the sales return liability (in thousands): Nine Months Ended September 30, 2021 2020 Beginning balance $ 9,192 $ 8,116 Addition to reserve for sales activity 115,374 84,119 Actual returns (110,996 ) (82,110 ) Change in estimate of sales returns (1,265 ) (46 ) Ending balance $ 12,305 $ 10,079

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2021
Financial Instruments Owned At Fair Value [Abstract]
Fair Value of Financial Instruments	4 . Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, customer deposits and sales return liability are reasonable estimates of their fair value because of the short maturity of these items. The fair value of the common stock warrant liability, contingent consideration, and the convertible feature related to the convertible note are discussed in Note 5. The fair value of the debt is based on the amount of future cash flows associated with the instrument discounted using the Company’s market rate. As of September 30, 2021, the carrying value of the long-term debt was not materially different from the fair value. As of September 30, 2021, the carrying value and fair value of the convertible note were as follows (in thousands): September 30, 2021 Carrying Value Fair Value Convertible note $ 46,657 $ 42,330

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	5 . Balance Sheet Components a. Inventories Inventories, net consist of the following (in thousands): September 30, December 31, 2021 2020 Raw materials $ 2,669 $ 3,788 Work in progress 4,325 10,710 Finished goods 40,278 21,254 Finished goods - right of return 4,257 3,416 $ 51,529 $ 39,168 b. Property and Equipment Property and equipment, net consist of the following (in thousands): September 30, December 31, 2021 2020 Leasehold improvements $ 2,605 $ 2,523 Manufacturing equipment and toolings 9,832 8,529 Computer equipment 1,637 2,522 Software 6,581 3,010 Furniture and fixtures 1,542 1,040 22,197 17,624 Less accumulated depreciation (7,311 ) (5,323 ) $ 14,886 $ 12,301 Depreciation expense for the three months ended September 30, 2021 and 2020 was $0.7 million and $0.9 million, respectively. Depreciation expense for the nine months ended September 30, 2021 and 2020 was $2.2 million and $1.4 million, respectively. c. Goodwill and Other Intangible Assets, net Following the sale of the miraDry business, the Company has one reporting unit, Plastic Surgery, formerly known as Breast Products. The Company evaluates goodwill for impairment at least annually on October 1 st The carrying amount of goodwill as of September 30, 2021 and December 31, 2020 were as follows (in thousands): Plastic Surgery miraDry Total Balances as of December 31, 2020 Goodwill 23,480 7,629 31,109 Accumulated impairment losses (14,278 ) (7,629 ) (21,907 ) Goodwill, net $ 9,202 $ — $ 9,202 Balances as of September 30, 2021 Goodwill 23,480 7,629 31,109 Accumulated impairment losses (14,278 ) (7,629 ) (21,907 ) Goodwill, net $ 9,202 $ — $ 9,202 The components of the Company’s other intangible assets consist of the following (in thousands): Average Amortization September 30, 2021 Period Gross Carrying Accumulated Intangible (in years) Amount Amortization Assets, net Intangibles with definite lives Customer relationships 10 $ 4,940 $ (4,132 ) $ 808 Trade names - finite life 12 800 (372 ) 428 Non-compete agreement 2 80 (80 ) — Regulatory approvals 1 670 (670 ) — Acquired FDA non-gel product approval 11 1,713 (1,713 ) — Manufacturing know-how 19 8,240 (1,455 ) 6,785 Total definite-lived intangible assets $ 16,443 $ (8,422 ) $ 8,021 Intangibles with indefinite lives Trade names - indefinite life — 450 — 450 Total indefinite-lived intangible assets $ 450 $ — $ 450 Average Amortization December 31, 2020 Period Gross Carrying Accumulated Intangible (in years) Amount Amortization Assets, net Intangibles with definite lives Customer relationships 10 $ 4,940 $ (3,856 ) $ 1,084 Trade names - finite life 12 800 (322 ) 478 Non-compete agreement 2 80 (80 ) — Regulatory approvals 1 670 (670 ) — Acquired FDA non-gel product approval 11 1,713 (1,713 ) — Manufacturing know-how 19 8,240 (865 ) 7,375 Total definite-lived intangible assets $ 16,443 $ (7,506 ) $ 8,937 Intangibles with indefinite lives Trade names - indefinite life — 450 — 450 Total indefinite-lived intangible assets $ 450 $ — $ 450 Amortization expense for both the three months ended September 30, 2021 and 2020 were $0.3 million. Amortization expense for the nine months ended September 30, 2021 and 2020 was $0.9 million and $1.0 million, respectively. The following table summarizes the future estimated amortization expense relating to the Company's definite-lived intangible assets as of September 30, 2021 (in thousands): Amortization Period Expense 2021 $ 305 2022 1,163 2023 1,092 2024 948 2025 805 Thereafter 3,708 $ 8,021 d. Accrued and Other Current Liabilities Accrued and other current liabilities consist of the following (in thousands): September 30, December 31, 2021 2020 Payroll and related expenses $ 4,389 $ 3,003 Accrued severance 452 2,900 Accrued commissions 3,494 4,734 Accrued manufacturing 252 225 Deferred and contingent consideration, current portion 3,195 10,146 Audit, consulting and legal fees — 48 Accrued sales and marketing expenses 96 300 Lease liabilities 1,618 1,588 Other 8,789 5,464 $ 22,285 $ 28,408 e . Accrued warranties The following table provides a rollforward of the accrued assurance-type warranties (in thousands): Nine Months Ended September 30, 2021 2020 Balance as of January 1 $ 1,934 $ 1,397 Warranty costs incurred during the period (270 ) (83 ) Changes in accrual related to warranties issued during the period 673 367 Changes in accrual related to pre-existing warranties 11 (5 ) Balance as of September 30 $ 2,348 $ 1,676 As of September 30, 2021 and 2020, both balances are included in “Warranty reserve and other long-term liabilities”. f. Liabilities measured at fair value Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Common stock warrants The Company’s common stock warrant liabilities are carried at fair value determined according to the fair value hierarchy described above. The Company has utilized an option pricing valuation model to determine the fair value of its outstanding common stock warrant liabilities. The inputs to the model include fair value of the common stock related to the warrant, exercise price of the warrant, expected term, expected volatility, risk-free interest rate and dividend yield. The warrants are valued using the fair value of common stock as of the measurement date. The Company estimates its expected stock volatility based on company-specific historical and implied volatility information of its stock. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the warrants. The Company has estimated a 0% dividend yield based on the expected dividend yield and the fact that the Company has never paid or declared dividends. As several significant inputs are not observable, the overall fair value measurement of the warrants is classified as Level 3. As of the current period ended September 30, 2021, all warrants have expired. Contingent consideration The Company assessed the fair value of the contingent consideration for future royalty payments related to the acquisition of BIOCORNEUM and the contingent consideration for the future milestone payments related to the acquisition of miraDry using a Monte-Carlo simulation model. The contingent consideration related to the acquisition of BIOCORNEUM consist of royalty obligations based on future net sales for a defined term, beginning in 2024. The significant assumption utilized in the fair value measurement was the revenue discount rate, which was 21.0%. The contingent consideration for milestone payments related to the acquisition of miraDry was based on the timing of achievement of target net sales, which is estimated based on an internal management forecast. The significant assumption utilized in the fair value measurement was the miraDry company discount rate, which was 11.2%. As these inputs are not observable, the overall fair value measurement of the contingent consideration is classified as Level 3. As of September 30, 2021, the remaining liability for the miraDry contingent consideration was approximately $31,000. Derivative liability Prior to the amendment, the Company assessed on a quarterly basis the fair value of the derivative liability associated with the conversion feature in the convertible note due in 2025. The conversion feature was initially bifurcated and recorded as a derivative liability on the condensed consolidated balance sheets with a corresponding discount at the date of issuance that netted against the principal amount of the note. The Company utilized a binomial lattice method to determine the fair value of the conversion feature, which utilized inputs including the common stock price, volatility of common stock, the risk-free interest rate and the probability of conversion to common shares at the Base Conversion Rate in the event of a major transaction (e.g. a change in control). As the probability of conversion is a significant unobservable input, the overall fair value measurement of the conversion feature was classified as Level 3. As a result of the amendment, the conversion feature met the c riteria for equity classification and has been reclassified to “Additional paid in capital” on the condensed consolidated balance sheet. The following tables present information about the Company’s liabilities that are measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020 and indicate the level of the fair value hierarchy utilized to determine such fair value (in thousands): Fair Value Measurements as of September 30, 2021 Using: Level 1 Level 2 Level 3 Total Liabilities: Liability for contingent consideration $ — $ — $ 106 $ 106 $ — $ — $ 106 $ 106 Fair Value Measurements as of December 31, 2020 Using: Level 1 Level 2 Level 3 Total Liabilities: Liability for contingent consideration $ — $ — $ 7,026 $ 7,026 Liability for derivative — — 26,570 26,570 $ — $ — $ 33,596 $ 33,596 The following table provides a rollforward of the aggregate fair values of the Company’s liabilities for which fair value is determined by Level 3 inputs (in thousands): Contingent consideration liability Derivative liability Balance, December 31, 2020 $ 7,026 $ 26,570 Change in fair value 49 14,460 Settlements (6,969 ) — Reclassification to equity — (41,030 ) Balance, September 30, 2021 $ 106 $ — The liability for the current portion of contingent consideration is included in “Accrued and other current liabilities” and the long-term portion is included in “Deferred and contingent consideration” in the condensed consolidated balance sheets. The Company recognized changes in the fair value of the derivative liability in “Change in fair value of derivative liability” in the condensed consolidated statement of operations and changes in the contingent consideration are recognized in “General and administrative” expense in the condensed consolidated statement of operations.

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	6 . Leases Components of lease expense were as follows: Three Months Ended September 30, Nine Months Ended September 30, Lease Cost Classification 2021 2020 2021 2020 Operating lease cost Operating expenses $ 405 $ 428 $ 1,239 $ 1,270 Operating lease cost Inventory 154 131 377 364 Sublease income Operating expenses (233 ) — (301 ) — Total operating lease cost $ 326 $ 559 $ 1,315 $ 1,634 Finance lease cost Amortization of right-of-use assets Operating expenses 8 10 26 31 Amortization of right-of-use assets Inventory 12 12 35 24 Interest on lease liabilities Other income (expense), net 2 3 6 7 Total finance lease cost $ 22 $ 25 $ 67 $ 62 Total lease cost $ 348 $ 584 $ 1,382 $ 1,696 As mentioned above in Note 2, as part of the sale of the miraDry business the Company entered into a sublease agreement whereby the Buyer will sublease the miraDry office space in Santa Clara, CA. The initial sublease term is for six months, with subsequent option periods for up to a total of twenty four months. During the initial term of six months, the Company expects cash receipts of approximately $0.5 million. Short-term lease expense for the three and nine months ended September 30, 2021 and 2020 was not material. Supplemental cash flow information related to operating and finance leases for the nine months ended September 30, 2021 Nine Months Ended September 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 1,261 $ 1,337 Operating cash outflows from finance leases 56 61 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 572 $ 1,242 Finance leases — 157 Supplemental balance sheet information related to operating and finance leases was as follows (in thousands, except lease term and discount rate): September 30, December 31, 2021 2020 Reported as: Other assets Operating lease right-of-use assets $ 6,524 $ 7,176 Finance lease right-of-use assets 97 158 Total right-of use assets $ 6,621 $ 7,334 Accrued and other current liabilities Operating lease liabilities $ 1,543 $ 1,504 Finance lease liabilities 75 84 Warranty reserve and other long-term liabilities Operating lease liabilities 5,315 5,946 Finance lease liabilities 41 77 Total lease liabilities $ 6,974 $ 7,611 Weighted average remaining lease term (years) Operating leases 4 5 Finance leases 2 2 Weighted average discount rate Operating leases 8.09 % 7.75 % Finance leases 6.48 % 6.15 % As of September 30, 2021, maturities of the Company’s operating and finance lease liabilities are as follows (in thousands): Period Operating leases Finance leases Total Remainder of 2021 $ 564 $ 27 $ 591 2022 2,035 58 2,093 2023 2,085 33 2,118 2024 1,629 4 1,633 2025 704 — 704 2026 and thereafter 1,221 — 1,221 Total lease payments $ 8,238 $ 122 $ 8,360 Less imputed interest 1,380 6 1,386 Total lease liabilities $ 6,858 $ 116 $ 6,974

Debt

Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt	7 . Debt On February 5, 2021, the Company entered into a Second Amended and Restated Credit and Security Agreement (Term Loan), by and among the Company, certain of the Company’s subsidiaries, the lenders party thereto from time to time and MidCap Financial Trust, as administrative agent and collateral agent (“Agent”) (the “Restated Term Loan Agreement”). The Restated Term Loan Agreement amends and restates the Company’s existing Amended and Restated Credit and Security Agreement, dated as of July 1, 2019. Pursuant to the Restated Term Loan Agreement, tranche 3 commitments were reduced from $15 million to $1 million and were advanced on the effective date of the Restated Term Loan Agreement and the remaining unfunded tranche of $15 million was revised to two $5 million As of September 30, 2021, there was $16.0 million of outstanding principal related to the term loans and $1.2 million of unamortized debt issuance costs which are included in “Long-term debt” on the condensed consolidated balance sheets. Also on February 5, 2021, the Company entered into a Third Amendment to the Amended and Restated Credit and Security Agreement (Revolving Loan), by and among the Company, the lenders party thereto from time to time, and the Agent (the “Revolving Loan Amendment”). The Revolving Loan Amendment modified the net revenue requirement in a manner consistent with the modification under the Restated Term Loan Agreement. In addition, the Revolving Loan Amendment made other conforming changes to the Restated Term Loan Agreement. As of September 30, 2021, there were no borrowings outstanding under the Revolving Loan. As of September 30, 2021, the unamortized debt issuance costs related to the revolving loan was approximately $0.1 million and was included in “Other assets” on the condensed consolidated balance sheets. The amortization of debt issuance costs on the term loan and the revolving loan for the three months ended September 30, 2021 and 2020 were $0.1 million and $0.2 million, respectively. The amortization of debt issuance costs on the term loan and revolving loan for the nine months ended September 30, 2021 and 2020 was $0.4 million and $0.7 million, respectively, and was included in interest expense in the condensed consolidated statements of operations. The Credit Agreements include customary affirmative and restrictive covenants and representations and warranties, including a financial covenant for minimum revenues, a financial covenant for minimum cash requirements, a covenant against the occurrence of a “change in control,” financial reporting obligations, and certain limitations on indebtedness, liens, investments, distributions, collateral, mergers or acquisitions, taxes, and deposit accounts. Upon the occurrence of an event of default, a default interest rate of an additional 5.0% may be applied to any outstanding principal balances, and MidCap may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Credit Agreements. The Company’s obligations under the Credit Agreements are secured by a security interest in substantially all of the Company’s assets. Convertible Note On September 28, 2021, the Company entered into a First Amendment (the “Amendment”) to Facility Agreement (the “Agreement”) with Deerfield Partners, L.P., as agent and lender (“Deerfield”). The Amendment provides for, among other things, the ability, at the sole option of Deerfield, to issue unregistered shares of the Company’s common stock upon the conversion of the Convertible Note (as defined in the Agreement). In addition, the Amendment provides that, in the event of a Major Transaction (as defined in the Convertible Note), no additional shares of the Company’s common stock shall be issued if the Share Price Result (as defined in the Convertible Note) is greater than $ 30.00 per share or less than $ 1.50 per share. Prior to the amendment, the conversion features in the outstanding convertible debt instrument were accounted for as a free-standing embedded derivative bifurcated from the principal balance of the Note, as (1) the conversion features were not clearly and closely related to the debt instrument and were not considered to be indexed to the Company’s equity, (2) the conversion features standing alone meet the definition of a derivative, and (3) the Note is not remeasured at fair value each reporting period with changes in fair value recorded in the condensed consolidated statement of operations. As a result of the amendment, the conversion feature no longer needed to be accounted for as a free-standing embedded derivative as it met the criteria for equity classification. As of the amendment date, the derivative liability was adjusted to a fair value of $41.0 million and has been reclassified to “Additional paid in capital” on the condensed consolidated balance sheet. As of September 30, 2021 three months ended September 30, 2021 million and $0.7 million, respectively. For the nine months ended September 30, 2021 and Both were included in interest expense in the condensed consolidated statements of operations CARES Act On July 30, 2021, the Company was notified by Silicon Valley Bank that they received payment in full from the Small Business Administration for the amount of the Company's PPP Loan and the Company's PPP Loan had been fully forgiven. For the quarter ended September 30, 2021, the Company recorded a gain on extinguishment of the PPP Loan of $6.7 million in “Other income (expense), net” within the condensed consolidated statement of operations. Future Principal Payments of Debt The future schedule of principal payments for all outstanding debt as of September 30, 2021 was as follows (in thousands): Fiscal Year Remainder of 2021 $ — 2022 — 2023 10,105 2024 5,895 2025 60,000 Total $ 76,000

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stockholders' Equity	8 . Stockholders’ Equity a. Authorized Stock The Company’s Amended and Restated Certificate of Incorporation authorizes the Company to issue 210,000,000 shares of common and preferred stock, consisting of 200,000,000 shares of common stock with $0.01 par value and 10,000,000 shares of preferred stock with $0.01 par value. As of September 30, 2021 and December 31, 2020, the Company had no preferred stock issued or outstanding. b. Common Stock Warrants On January 17, 2013, the Company entered into a Loan and Security Agreement, or the Original Term Loan Agreement, with Oxford Finance, LLC, or Oxford. On June 30, 2014, the Company entered into an Amended and Restated Loan and Security Agreement, or the Amended Term Loan Agreement, with Oxford. In connection with the Original Term Loan Agreement and the Amended Term Loan Agreement, the Company issued to Oxford (i) seven-year seven-year c. Stock Option Plans As of September 30, 2021, a total of 1,860,554 shares of the Company’s common stock were available for issuance under the 2014 Plan. As of September 30, 2021, inducement grants for 1,904,425 shares of common stock have been awarded, and 638,710 shares of common stock were available for future issuance under the Inducement Plan. Options under the 2007 Plan and the 2014 Plan may be granted for periods of up to ten years as determined by the Company’s board of directors, provided, however, that (i) the exercise price of an ISO shall not be less than 100% of the estimated fair value of the shares on the date of grant, and (ii) the exercise price of an ISO granted to a more than 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. An NSO has no such exercise price limitations. NSOs under the Inducement Plan may be granted for periods of up to ten years as determined by the board of directors, provided, the exercise price will not be less than 100% of the estimated fair value of the shares on the date of grant. Options generally vest with 25% of the grant vesting on the first anniversary and the balance vesting monthly on a straight-lined basis over the requisite service period of three additional years for the award. Additionally, options have been granted to certain key executives that vest upon achievement of performance conditions based on performance targets as defined by the board of directors, which have included net sales targets and defined corporate objectives over the performance period with possible payout ranging from 0% to 100% of the target award. Compensation expense is recognized on a straight-lined basis over the vesting term of one year based upon the probable performance target that will be met. The vesting provisions of individual options may vary but provide for vesting of at least 25% per year. The following summarizes all option activity under the 2007 Plan, 2014 Plan and Inducement Plan: Weighted Weighted average average remaining Option exercise contractual Shares price term (year) Balances at December 31, 2020 1,959,501 $ 4.79 5.92 Exercised (36,363 ) 3.99 Forfeited (138,859 ) 5.15 Balances at September 30, 2021 1,784,279 $ 4.78 5.50 For stock-based awards the Company recognizes compensation expense based on the grant date fair value using the Black-Scholes option valuation model. Stock-based compensation expense related to stock options for the three and nine months ended September 30, 2021 were $0.1 million and $0.4 million, respectively. There was no stock-based compensation expense related to stock options for the three and nine months ended September 30, 2020. As of September 30, 2021, unrecognized compensation costs related to stock options was $1.7 million. d. Restricted Stock Units The Company has issued restricted stock unit awards, or RSUs, under the 2014 Plan and the Inducement Plan. The RSUs issued to employees generally vest on a straight-line basis annually over a 3-year requisite service period. RSUs issued to non-employees generally vest either monthly or annually over the service term. In 2020, the Company implemented a sell-to-cover program for employees who elect to sell shares to cover any withholding taxes due upon vesting. For employees who do not elect to sell shares to cover withholding taxes, the Company nets shares upon vesting and pays the withholding taxes directly. Activity related to RSUs is set forth below: Weighted average Number grant date of shares fair value Balances at December 31, 2020 3,093,790 $ 6.97 Granted 1,597,983 7.38 Vested (1,174,753 ) 6.99 Forfeited (392,728 ) 6.98 Balances at September 30, 2021 3,124,292 $ 7.17 Stock-based compensation expense for RSUs for the three months ended September 30, 2021 and 2020 was $2.1 million and $1.5 million, respectively. Stock-based compensation expense for RSUs for the nine months ended September 30, 2021 and 2020 was $7.3 million and $4.9 million, respectively. As of September 30, 2021, there was $11.1 million of total unrecognized compensation costs related to non-vested RSU awards. The cost is expected to be recognized over a weighted average period of approximately 2.05 years. e. Employee Stock Purchase Plan The Company’s board of directors adopted the 2014 Employee Stock Purchase Plan, or ESPP, in July 2014, and the stockholders approved the ESPP in October 2014. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP provides for offering periods not to exceed 27 months, and each offering period will include purchase periods, which will be the approximately six-month During the nine months ended September 30, 2021, employees purchased 199,071 shares of common stock at a weighted average price of $3.38 per share. As of September 30, 2021, the number of shares of common stock available for future issuance was 1,253,615. The Company estimated the fair value of employee stock purchase rights using the Black-Scholes model. Stock-based compensation expense related to the ESPP was $0.1 million for both the three months ended September 30, 2021 and 2020. Stock-based compensation expense related to the ESPP was $0.4 million for both the nine months ended September 30, 2021 and 2020. f . Significant Modifications During the nine months ended September 30, 2021 and 2020, there were no material modifications of equity awards.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	9 . Earnings (Loss) Per Share Basic earnings (loss) per share is calculated by dividing the income (loss) from continuing and discontinued operations by the weighted average outstanding common shares for basic EPS for the period. Diluted EPS includes the potential dilution of common stock equivalent shares that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator for continuing operations: Income (loss) from continuing operations used in computing basic earnings (loss) per share $ 28,503 $ (1,487 ) $ (46,647 ) $ (46,817 ) Convertible note interest expense 1,392 - - - Fair value adjustments to the derivative liability (35,550 ) - - - Losses from continuing operations used in computing diluted loss per share $ (5,655 ) $ (1,487 ) $ (46,647 ) $ (46,817 ) Numerator for discontinued operations: Income (loss) from discontinued operations, net of income taxes (93 ) (4,334 ) 233 (21,893 ) Income (loss) from discontinued operations used in computing basic and diluted earnings (loss) per share $ (93 ) $ (4,334 ) $ 233 $ (21,893 ) Numerator for losses: Net income (loss) used in computing basic earnings (loss) per share $ 28,410 $ (5,821 ) $ (46,414 ) $ (68,710 ) Net loss used in computing diluted loss per share $ (5,748 ) $ (5,821 ) $ (46,414 ) $ (68,710 ) Denominator: Weighted average outstanding common shares for basic earnings (loss) per share 58,005,784 50,394,858 56,680,594 50,155,623 Dilutive effect of the convertible note 14,634,146 - - - Weighted average outstanding common shares for diluted loss per share 72,639,930 50,394,858 56,680,594 50,155,623 Basic earnings (loss) per share: Continuing operations $ 0.49 $ (0.03 ) $ (0.82 ) $ (0.93 ) Discontinued operations $ (0.00 ) $ (0.09 ) $ 0.00 $ (0.44 ) Basic earnings (loss) per share $ 0.49 $ (0.12 ) $ (0.82 ) $ (1.37 ) Diluted earnings (loss) per share: Continuing operations $ (0.08 ) $ (0.03 ) $ (0.82 ) $ (0.93 ) Discontinued operations $ (0.00 ) $ (0.09 ) $ 0.00 $ (0.44 ) Diluted earnings (loss) per share $ (0.08 ) $ (0.12 ) $ (0.82 ) $ (1.37 ) The potentially dilutive impact from stock options and RSUs is calculated under the treasury stock method. Under this method, proceeds based on the exercise price and unearned compensation are assumed to be used to repurchase shares on the open market at the average market price for the period, reducing the number of potential new shares to be issued and sometimes causing an antidilutive effect. The potentially dilutive impact from the Convertible Note is calculated under the if-converted method until the conversion date. After the conversion date, the converted shares are included in weighted-average common shares outstanding for basic EPS. The Company excluded the following potentially dilutive securities, outstanding for the three and nine months ended September 30, 2021 and 2020, from the computation of diluted net loss per share attributable to common stockholders for the three and nine months ended September 30, 2021 and 2020 because they had an anti-dilutive impact due to the net loss attributable to common stockholders incurred for the periods. Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Stock issuable upon conversion of convertible note — 14,634,146 14,634,146 11,002,710 Stock options to purchase common stock 1,582,901 34,308 1,629,493 862,278 Unvested RSUs 2,322,816 1,445,486 2,049,832 1,531,084 3,905,717 16,113,940 18,313,471 13,396,072

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	10 . Income Taxes The Company the Company

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Information	1 1 . Segment Information Following the sale of the miraDry business on June 10, 2021, the Company has one reportable segment named Plastic Surgery, formally known as Breast Products. The Plastic Surgery segment focuses on sales of silicone gel breast implants, tissue expanders and scar management products under the brands Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The net sales, net operating loss and net assets for the Plastic Surgery segment are presented in the condensed consolidated statement of operations and condensed consolidated balance sheets as continuing operations.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	1 2 . Commitments and Contingencies The Company is subject to claims and assessment from time to time in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Product Liability Litigation On October 7, 2019, a lawsuit was filed in the Superior Court of the State of California against the Company and Silimed Industria de Implantes Ltda. (the Company’s former contract manufacturer). The lawsuit alleges that the Company’s textured breast implants caused certain of the plaintiffs to develop a condition known as breast implant associated anaplastic large cell lymphoma (“BIA-ALCL”), and that the Company is liable to the plaintiffs based on claims for strict liability (failure to warn), strict liability (defective manufacture), negligence and loss of consortium. On January 21, 2020, the Company filed a demurrer to the plaintiff’s complaint, which demurrer the Court granted in a tentative ruling dated March 9, 2021 with leave to replead. The Plaintiffs filed an amended complaint on April 6, 2021 and the Company filed a demurrer to that complaint on May 6, 2021. On October 25, 2021, the Court issued a ruling granting the Company’s demurrer in-part and denying it in-part, and gave plaintiffs twenty days to file an amendment complaint. The Company intends to vigorously defend itself in this lawsuit. Given the nature of this case, the Company is unable to estimate the reasonably possible loss or range of loss, if any, arising from this matter. On September 23, 2020, a lawsuit was filed in the Eastern District of Tennessee against the Company. The lawsuit alleges that the Company’s textured breast implants caused certain of the plaintiffs to develop a condition known as breast implant associated anaplastic large cell lymphoma (“BIA-ALCL”), and that the Company is liable to the plaintiffs based on claims for negligence, strict liability (manufacturing defects), strict liability (failure to warn), breach of express and implied warranties, and punitive damages. The Company filed a motion to dismiss the complaint on December 7, 2020. Briefing on the motion is complete and oral argument is presently scheduled for January 2022. The Company intends to vigorously defend itself in this lawsuit. Given the nature of this case, the Company is unable to estimate the reasonably possible loss or range of loss, if any, arising from this matter.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	a. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Sientra, Inc. (“Sientra”, the “Company”, “we”, “our”, or “us”) in this Quarterly Report on Form 10-Q have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and the rules and regulations of the U.S. Securities and Exchange Commission, or SEC. Accordingly, they do not include certain footnotes and financial presentations normally required under accounting principles generally accepted in the United States of America for complete financial reporting. The interim financial information is unaudited, but reflects all normal adjustments and accruals which are, in the opinion of management, considered necessary to provide a fair presentation for the interim periods presented. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 11, 2021, or the Annual Report. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period. As a result of the miraDry Sale discussed in Note 2, the miraDry business met the criteria to be reported as discontinued operations. Therefore, the Company is reporting the historical results of miraDry, including the results of operations, cash flows, and related assets and liabilities, as discontinued operations for all periods presented herein through the date of the Sale. Unless otherwise noted, the accompanying notes to the unaudited condensed consolidated financial statements have all been revised to reflect continuing operations only. As discussed in Note 11, following the Sale the Company has one operating segment in continuing operations named Plastic Surgery, formerly known as Breast Products.
Liquidity	b. Liquidity Since the Company’s inception, it has incurred significant net operating losses and the Company anticipates that losses will continue in the near term. The Company expects its operating expenses will remain consistent with the current period and will need to generate significant net sales to achieve profitability. To date, the Company has funded operations primarily with proceeds from the sales of preferred stock, borrowings under term loans and the convertible note, sales of products since 2012, and the proceeds from the sale of common stock in public offerings. To fund ongoing operating and capital needs, the Company may need to raise additional capital in the future through the sale of equity securities and incremental debt financing. Sale of the miraDry business Refer to Note 2 for details on the sale of the miraDry business. Debt financing – recent developments Refer to Note 7 for a full description and updates to all of the Company’s long-term debt, revolving line of credit, convertible note, and Paycheck Protection Program (PPP) loan. Equity financing – recent developments On February 8, 2021, the Company completed a follow-on public offering of 5,410,628 shares of common stock at $6.75 per share, as well as 811,594 additional shares of common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. Net proceeds were approximately $39.2 million after deducting underwriting discounts and commissions of approximately $2.5 million and offering expenses of approximately $0.3 million . As of September 30, 2021, the Company had cash and cash equivalents of $66.1 million. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company believes that its cash and cash equivalents will be sufficient to fund its operations for at least the next 12 months.
Recent Accounting Pronouncements	c. Recent Accounting Pronouncements Recently Adopted Accounting Standards In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes
Risks and Uncertainties	d. Risks and Uncertainties As an aesthetics company, surgical procedures involving the Company’s breast products are susceptible to local and national government restrictions, such as social distancing, vaccination requirements, “shelter in place” orders and business closures. The inability or limited ability to perform such non-emergency procedures significantly harmed the Company’s revenues since the second quarter of 2020 and continued to harm the Company’s revenues during the nine months ended September 30, 2021. While many states have lifted certain restrictions on non-emergency procedures, the Company will likely continue to experience future harm to its revenues while existing or new restrictions remain in place. It is not possible to accurately predict the length or severity of the COVID-19 pandemic or the timing for a broad and sustained ability to perform non-emergency procedures involving the Company’s products. The Company continues to monitor and assess new information related to the COVID-19 pandemic, the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. Further, the spread of COVID-19 has caused the Company to modify workforce practices, and the Company may take further actions determined to be in the best interests of the Company’s employees or as required by governments. The continued spread of COVID-19, or another infectious disease, could also result in delays or disruptions in the Company’s supply chain or adversely affect the Company’s manufacturing facilities and personnel. Further, trade and/or national security protection policies may be adjusted as a result of the COVID-19 pandemic, such as actions by governments that limit, restrict or prevent the movement of certain goods into a country and/or region, and current U.S./China trade relations may be further exacerbated by the pandemic. The estimates used for, but not limited to, determining the collectability of accounts receivable, fair value of long-lived assets and goodwill, and sales returns liability required could be impacted by the pandemic. While the full impact of COVID-19 is unknown at this time, the Company has made appropriate estimates based on the facts and circumstances available as of the reporting date. These estimates may change as new events occur and additional information is obtained.
Reclassifications	e. Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Revenue Recognition	The Company generates revenue primarily through the sale and delivery of promised goods or services to customers. Sales prices are documented in the executed sales contract, purchase order or order acknowledgement prior to the transfer of control to the customer. Typical payment terms are 30 days. Revenue contracts may include multiple products or services, each of which is considered a separate performance obligation. Performance obligations typically include the delivery of promised products, such as breast implants, tissue expanders, and BIOCORNEUM, along with service-type warranties. Other deliverables are sometimes promised but are ancillary and insignificant in the context of the contract as a whole . Revenue is allocated to each performance obligation based on its relative standalone selling price. The Company determines standalone selling prices based on observable prices for all performance obligations with the exception of the service-type warranty under the Platinum20 Limited Warranty Program, or Platinum20 , which is based on the expected cost plus margin approach. Inputs into the expected cost plus margin approach include historical incidence rates, estimated replacement costs, estimated financial assistance payouts and an estimated margin. The liability for unsatisfied performance obligations under the service warranty as of September 30, 2021 were as follows: Nine Months Ended September 30, 2021 Balance as of December 31, 2020 $ 1,945 Additions and adjustments 1,379 Revenue recognized (411 ) Balance as of September 30, 2021 $ 2,913 Revenue for service warranties are recognized ratably over the term of the agreements. Specifically for Platinum20, the performance obligation is satisfied at the time that the benefits are provided and are expected to be satisfied over the following 3 to 24 month period for financial assistance and 20 years for product replacement. For delivery of promised products, control transfers and revenue is recognized upon shipment, unless the contractual arrangement requires transfer of control when products reach their destination, for which revenue is recognized once the product arrives at its destination. A portion of the Company’s revenue is generated from the sale of consigned inventory of breast implants and tissue expanders maintained at doctor, hospital, and clinic locations. For these products, revenue is recognized at the time the Company is notified by the customer that the product has been used, not when the consigned products are delivered to the customer’s location. Sales Return Liability With the exception of the Company’s BIOCORNEUM scar management products, the Company allows for the return of products from customers within six months after the original sale, which is accounted for as variable consideration. A sales return liability is established based on estimated returns using relevant historical experience taking into consideration recent gross sales and notifications of pending returns, as adjusted for changes in recent industry events and trends. The estimated sales returns are recorded as a reduction of revenue and as a sales return liability in the same period revenue is recognized. Actual sales returns in any future period are inherently uncertain and thus may differ from the estimates. If actual sales returns differ significantly from the estimates, an adjustment to revenue in the current or subsequent period would be recorded. The following table provides a rollforward of the sales return liability (in thousands): Nine Months Ended September 30, 2021 2020 Beginning balance $ 9,192 $ 8,116 Addition to reserve for sales activity 115,374 84,119 Actual returns (110,996 ) (82,110 ) Change in estimate of sales returns (1,265 ) (46 ) Ending balance $ 12,305 $ 10,079

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2021
Discontinued Operations And Disposal Groups [Abstract]
Schedule of Disposal Groups Including Discontinued Operations Balance Sheet and Income Statement	The following table presents the aggregate carrying amount s of major classes of assets and liabilities of discontinued operations (in thousands): September 30, December 31, 2021 2020 Assets of discontinued operations: Accounts receivable, net $ — $ 3,732 Inventories, net — 9,480 Prepaid expenses and other current assets 4 263 Current assets of discontinued operations 4 13,475 Property and equipment, net — 805 Total assets of discontinued operations $ 4 $ 14,280 Liabilities of discontinued operations: Accounts payable $ 6 $ 704 Accrued and other current liabilities 495 3,982 Total liabilities of discontinued operations $ 501 $ 4,686 Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Net sales $ — $ 3,888 $ 9,347 $ 11,488 Cost of goods sold — 1,286 4,805 4,846 Gross profit — 2,602 4,542 6,642 Operating expenses 57 7,034 1,744 28,571 Income (loss) from operations of discontinued operations (57 ) (4,432 ) 2,798 (21,929 ) Other income (expense), net — 98 (77 ) 36 Income (loss) from discontinued operations before income taxes (57 ) (4,334 ) 2,721 (21,893 ) Loss on sale of discontinued operations before income taxes (36 ) — (2,488 ) — Total income (loss) from discontinued operations before income taxes (93 ) (4,334 ) 233 (21,893 ) Income tax expense (benefit) — — — — Income (loss) from discontinued operations, net of income taxes $ (93 ) $ (4,334 ) $ 233 $ (21,893 )

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue From Contract With Customer [Abstract]
Schedule of Liability for Unsatisfied Performance Obligations Under Service Warranty and Deliverables Under Certain Marketing Programs	The liability for unsatisfied performance obligations under the service warranty as of September 30, 2021 were as follows: Nine Months Ended September 30, 2021 Balance as of December 31, 2020 $ 1,945 Additions and adjustments 1,379 Revenue recognized (411 ) Balance as of September 30, 2021 $ 2,913
Schedule of Rollforward of Sales Return Liability	The following table provides a rollforward of the sales return liability (in thousands): Nine Months Ended September 30, 2021 2020 Beginning balance $ 9,192 $ 8,116 Addition to reserve for sales activity 115,374 84,119 Actual returns (110,996 ) (82,110 ) Change in estimate of sales returns (1,265 ) (46 ) Ending balance $ 12,305 $ 10,079

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Financial Instruments Owned At Fair Value [Abstract]
Schedule of Carrying Value and Fair Value of Convertible Note	As of September 30, 2021, the carrying value and fair value of the convertible note were as follows (in thousands): September 30, 2021 Carrying Value Fair Value Convertible note $ 46,657 $ 42,330

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Schedule of inventories, net	Inventories, net consist of the following (in thousands): September 30, December 31, 2021 2020 Raw materials $ 2,669 $ 3,788 Work in progress 4,325 10,710 Finished goods 40,278 21,254 Finished goods - right of return 4,257 3,416 $ 51,529 $ 39,168
Schedule of property and equipment, net	Property and equipment, net consist of the following (in thousands): September 30, December 31, 2021 2020 Leasehold improvements $ 2,605 $ 2,523 Manufacturing equipment and toolings 9,832 8,529 Computer equipment 1,637 2,522 Software 6,581 3,010 Furniture and fixtures 1,542 1,040 22,197 17,624 Less accumulated depreciation (7,311 ) (5,323 ) $ 14,886 $ 12,301
Schedule of Carrying Amount of Goodwill	The carrying amount of goodwill as of September 30, 2021 and December 31, 2020 were as follows (in thousands): Plastic Surgery miraDry Total Balances as of December 31, 2020 Goodwill 23,480 7,629 31,109 Accumulated impairment losses (14,278 ) (7,629 ) (21,907 ) Goodwill, net $ 9,202 $ — $ 9,202 Balances as of September 30, 2021 Goodwill 23,480 7,629 31,109 Accumulated impairment losses (14,278 ) (7,629 ) (21,907 ) Goodwill, net $ 9,202 $ — $ 9,202
Schedule of Other Intangible assets	The components of the Company’s other intangible assets consist of the following (in thousands): Average Amortization September 30, 2021 Period Gross Carrying Accumulated Intangible (in years) Amount Amortization Assets, net Intangibles with definite lives Customer relationships 10 $ 4,940 $ (4,132 ) $ 808 Trade names - finite life 12 800 (372 ) 428 Non-compete agreement 2 80 (80 ) — Regulatory approvals 1 670 (670 ) — Acquired FDA non-gel product approval 11 1,713 (1,713 ) — Manufacturing know-how 19 8,240 (1,455 ) 6,785 Total definite-lived intangible assets $ 16,443 $ (8,422 ) $ 8,021 Intangibles with indefinite lives Trade names - indefinite life — 450 — 450 Total indefinite-lived intangible assets $ 450 $ — $ 450 Average Amortization December 31, 2020 Period Gross Carrying Accumulated Intangible (in years) Amount Amortization Assets, net Intangibles with definite lives Customer relationships 10 $ 4,940 $ (3,856 ) $ 1,084 Trade names - finite life 12 800 (322 ) 478 Non-compete agreement 2 80 (80 ) — Regulatory approvals 1 670 (670 ) — Acquired FDA non-gel product approval 11 1,713 (1,713 ) — Manufacturing know-how 19 8,240 (865 ) 7,375 Total definite-lived intangible assets $ 16,443 $ (7,506 ) $ 8,937 Intangibles with indefinite lives Trade names - indefinite life — 450 — 450 Total indefinite-lived intangible assets $ 450 $ — $ 450
Schedule of Future Estimated Amortization Expense	The following table summarizes the future estimated amortization expense relating to the Company's definite-lived intangible assets as of September 30, 2021 (in thousands): Amortization Period Expense 2021 $ 305 2022 1,163 2023 1,092 2024 948 2025 805 Thereafter 3,708 $ 8,021
Schedule of accrued and other current liabilities	Accrued and other current liabilities consist of the following (in thousands): September 30, December 31, 2021 2020 Payroll and related expenses $ 4,389 $ 3,003 Accrued severance 452 2,900 Accrued commissions 3,494 4,734 Accrued manufacturing 252 225 Deferred and contingent consideration, current portion 3,195 10,146 Audit, consulting and legal fees — 48 Accrued sales and marketing expenses 96 300 Lease liabilities 1,618 1,588 Other 8,789 5,464 $ 22,285 $ 28,408
Schedule of rollforward of the accrued assurance-type warrantie	The following table provides a rollforward of the accrued assurance-type warranties (in thousands): Nine Months Ended September 30, 2021 2020 Balance as of January 1 $ 1,934 $ 1,397 Warranty costs incurred during the period (270 ) (83 ) Changes in accrual related to warranties issued during the period 673 367 Changes in accrual related to pre-existing warranties 11 (5 ) Balance as of September 30 $ 2,348 $ 1,676
Schedule of Company's Liabilities that are Measured at Fair Value on a Recurring Basis	The following tables present information about the Company’s liabilities that are measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020 and indicate the level of the fair value hierarchy utilized to determine such fair value (in thousands): Fair Value Measurements as of September 30, 2021 Using: Level 1 Level 2 Level 3 Total Liabilities: Liability for contingent consideration $ — $ — $ 106 $ 106 $ — $ — $ 106 $ 106 Fair Value Measurements as of December 31, 2020 Using: Level 1 Level 2 Level 3 Total Liabilities: Liability for contingent consideration $ — $ — $ 7,026 $ 7,026 Liability for derivative — — 26,570 26,570 $ — $ — $ 33,596 $ 33,596
Schedule of Aggregate Fair Values of Company's Liabilities for which Fair Value is Determined by Level 3 Inputs	The following table provides a rollforward of the aggregate fair values of the Company’s liabilities for which fair value is determined by Level 3 inputs (in thousands): Contingent consideration liability Derivative liability Balance, December 31, 2020 $ 7,026 $ 26,570 Change in fair value 49 14,460 Settlements (6,969 ) — Reclassification to equity — (41,030 ) Balance, September 30, 2021 $ 106 $ —

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Components of Lease Expense	Components of lease expense were as follows: Three Months Ended September 30, Nine Months Ended September 30, Lease Cost Classification 2021 2020 2021 2020 Operating lease cost Operating expenses $ 405 $ 428 $ 1,239 $ 1,270 Operating lease cost Inventory 154 131 377 364 Sublease income Operating expenses (233 ) — (301 ) — Total operating lease cost $ 326 $ 559 $ 1,315 $ 1,634 Finance lease cost Amortization of right-of-use assets Operating expenses 8 10 26 31 Amortization of right-of-use assets Inventory 12 12 35 24 Interest on lease liabilities Other income (expense), net 2 3 6 7 Total finance lease cost $ 22 $ 25 $ 67 $ 62 Total lease cost $ 348 $ 584 $ 1,382 $ 1,696
Supplemental Cash Flow Information Related to Operating and Finance Leases	Supplemental cash flow information related to operating and finance leases for the nine months ended September 30, 2021 Nine Months Ended September 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 1,261 $ 1,337 Operating cash outflows from finance leases 56 61 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 572 $ 1,242 Finance leases — 157
Supplemental Balance Sheet Information Related to Operating and Finance Leases	Supplemental balance sheet information related to operating and finance leases was as follows (in thousands, except lease term and discount rate): September 30, December 31, 2021 2020 Reported as: Other assets Operating lease right-of-use assets $ 6,524 $ 7,176 Finance lease right-of-use assets 97 158 Total right-of use assets $ 6,621 $ 7,334 Accrued and other current liabilities Operating lease liabilities $ 1,543 $ 1,504 Finance lease liabilities 75 84 Warranty reserve and other long-term liabilities Operating lease liabilities 5,315 5,946 Finance lease liabilities 41 77 Total lease liabilities $ 6,974 $ 7,611 Weighted average remaining lease term (years) Operating leases 4 5 Finance leases 2 2 Weighted average discount rate Operating leases 8.09 % 7.75 % Finance leases 6.48 % 6.15 %
Maturities of Operating and Finance Lease Liabilities	As of September 30, 2021, maturities of the Company’s operating and finance lease liabilities are as follows (in thousands): Period Operating leases Finance leases Total Remainder of 2021 $ 564 $ 27 $ 591 2022 2,035 58 2,093 2023 2,085 33 2,118 2024 1,629 4 1,633 2025 704 — 704 2026 and thereafter 1,221 — 1,221 Total lease payments $ 8,238 $ 122 $ 8,360 Less imputed interest 1,380 6 1,386 Total lease liabilities $ 6,858 $ 116 $ 6,974

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Future Principal Payments for Outstanding Debt	The future schedule of principal payments for all outstanding debt as of September 30, 2021 was as follows (in thousands): Fiscal Year Remainder of 2021 $ — 2022 — 2023 10,105 2024 5,895 2025 60,000 Total $ 76,000

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of option activity	The following summarizes all option activity under the 2007 Plan, 2014 Plan and Inducement Plan: Weighted Weighted average average remaining Option exercise contractual Shares price term (year) Balances at December 31, 2020 1,959,501 $ 4.79 5.92 Exercised (36,363 ) 3.99 Forfeited (138,859 ) 5.15 Balances at September 30, 2021 1,784,279 $ 4.78 5.50
Summary of RSUs activity	Activity related to RSUs is set forth below: Weighted average Number grant date of shares fair value Balances at December 31, 2020 3,093,790 $ 6.97 Granted 1,597,983 7.38 Vested (1,174,753 ) 6.99 Forfeited (392,728 ) 6.98 Balances at September 30, 2021 3,124,292 $ 7.17

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of earnings (loss) per share, basic and diluted	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator for continuing operations: Income (loss) from continuing operations used in computing basic earnings (loss) per share $ 28,503 $ (1,487 ) $ (46,647 ) $ (46,817 ) Convertible note interest expense 1,392 - - - Fair value adjustments to the derivative liability (35,550 ) - - - Losses from continuing operations used in computing diluted loss per share $ (5,655 ) $ (1,487 ) $ (46,647 ) $ (46,817 ) Numerator for discontinued operations: Income (loss) from discontinued operations, net of income taxes (93 ) (4,334 ) 233 (21,893 ) Income (loss) from discontinued operations used in computing basic and diluted earnings (loss) per share $ (93 ) $ (4,334 ) $ 233 $ (21,893 ) Numerator for losses: Net income (loss) used in computing basic earnings (loss) per share $ 28,410 $ (5,821 ) $ (46,414 ) $ (68,710 ) Net loss used in computing diluted loss per share $ (5,748 ) $ (5,821 ) $ (46,414 ) $ (68,710 ) Denominator: Weighted average outstanding common shares for basic earnings (loss) per share 58,005,784 50,394,858 56,680,594 50,155,623 Dilutive effect of the convertible note 14,634,146 - - - Weighted average outstanding common shares for diluted loss per share 72,639,930 50,394,858 56,680,594 50,155,623 Basic earnings (loss) per share: Continuing operations $ 0.49 $ (0.03 ) $ (0.82 ) $ (0.93 ) Discontinued operations $ (0.00 ) $ (0.09 ) $ 0.00 $ (0.44 ) Basic earnings (loss) per share $ 0.49 $ (0.12 ) $ (0.82 ) $ (1.37 ) Diluted earnings (loss) per share: Continuing operations $ (0.08 ) $ (0.03 ) $ (0.82 ) $ (0.93 ) Discontinued operations $ (0.00 ) $ (0.09 ) $ 0.00 $ (0.44 ) Diluted earnings (loss) per share $ (0.08 ) $ (0.12 ) $ (0.82 ) $ (1.37 )
Schedule of potentially dilutive securities excluded from the computation of diluted net loss per share attributable to common stockholders	The Company excluded the following potentially dilutive securities, outstanding for the three and nine months ended September 30, 2021 and 2020, from the computation of diluted net loss per share attributable to common stockholders for the three and nine months ended September 30, 2021 and 2020 because they had an anti-dilutive impact due to the net loss attributable to common stockholders incurred for the periods. Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Stock issuable upon conversion of convertible note — 14,634,146 14,634,146 11,002,710 Stock options to purchase common stock 1,582,901 34,308 1,629,493 862,278 Unvested RSUs 2,322,816 1,445,486 2,049,832 1,531,084 3,905,717 16,113,940 18,313,471 13,396,072

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 08, 2021	Mar. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents			$ 66,127	$ 54,967	$ 63,483
Follow-on Offering | Common stock
Summary Of Significant Accounting Policies [Line Items]
Issuance of/proceeds from common stock (in shares)	5,410,628	6,222,222
Public offering price (in dollars per share)	$ 6.75
Additional shares granted to underwriters	811,594
Proceeds from the issuance of common stock, net of underwriting discounts, commissions and offering expenses	$ 39,200
Payment of underwriting discounts and commissions and offering expenses	2,500
Offering expenses	$ 300

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	Jun. 10, 2021	Oct. 31, 2021	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2020
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Receivable			$ 26,453	$ 26,453	$ 26,453	$ 19,771
Accounts payable			6,300	6,300	$ 6,300	$ 5,799
Transition Services Agreement
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Post-closing services period					6 months
TSA fees and cost reimbursements in operating expenses from continuing operations					$ 100
Payments relating to the TSA services					300
Receivable relating to TSA services				2,300
Remittance relating to TSA services				2,200
Accounts payable			100	100	$ 100
Sublease Agreement
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Sublease term initial period					6 months
First option period					24 months
Subsequent option periods					24 months
Sublease Income					$ 500
Sublease Agreement | General and Administrative Expenses
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Sublease Income			200		300
Other Current Assets | Transition Services Agreement
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Receivable	$ 100
miraDry
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Proceeds from sale of assets	10,000
Net upfront cash proceeds	$ 11,300
Loss on sale of businesses					2,500
miraDry | Subsequent Event
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Payment for post close changes in net asset value		$ 3,200
miraDry | Accrued and Other Current Liabilities
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Escrow liability			$ 3,200	$ 3,200	$ 3,200

Discontinued Operations - Summa

Discontinued Operations - Summary of Aggregate Carrying Amounts of Major Classes of Assets and Liabilities of Discontinued Operations (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets of discontinued operations:
Accounts receivable, net		$ 3,732
Inventories, net		9,480
Prepaid expenses and other current assets	$ 4	263
Current assets of discontinued operations	4	13,475
Property and equipment, net		805
Total assets of discontinued operations	4	14,280
Liabilities of discontinued operations:
Accounts payable	6	704
Accrued and other current liabilities	495	3,982
Total liabilities of discontinued operations	$ 501	$ 4,686

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Information Regarding the Results of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Discontinued Operation Income Loss From Discontinued Operation Disclosures [Abstract]
Net sales		$ 3,888	$ 9,347	$ 11,488
Cost of goods sold		1,286	4,805	4,846
Gross profit		2,602	4,542	6,642
Operating expenses	$ 57	7,034	1,744	28,571
Income (loss) from operations of discontinued operations	(57)	(4,432)	2,798	(21,929)
Other income (expense), net		98	(77)	36
Income (loss) from discontinued operations before income taxes	(57)	(4,334)	2,721	(21,893)
Loss on sale of discontinued operations before income taxes	(36)		(2,488)
Total income (loss) from discontinued operations before income taxes	(93)	(4,334)	233	(21,893)
Income (loss) from discontinued operations, net of income taxes	$ (93)	$ (4,334)	$ 233	$ (21,893)

Revenue (Details 1)

Revenue (Details 1) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-10-01	Sep. 30, 2021
Product Replacement
Revenue From Contracts With Customers [Line Items]
Performance obligation satisfying period	20 years
Breast Products and Consumable miraDry products
Revenue From Contracts With Customers [Line Items]
Performance obligation satisfying period	30 days
Maximum | Financial Assistance
Revenue From Contracts With Customers [Line Items]
Performance obligation satisfying period	24 months
Minimum | Financial Assistance
Revenue From Contracts With Customers [Line Items]
Performance obligation satisfying period	3 months

Revenue - Schedule of Liability

Revenue - Schedule of Liability for Unsatisfied Performance Obligations Under Service Warranty and Deliverables Under Certain Marketing Programs (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Change In Contract With Customer Liability [Abstract]
Balance as of December 31, 2020	$ 1,945
Additions and adjustments	1,379
Revenue recognized	(411)
Balance as of September 30, 2021	$ 2,913

Revenue (Details)

Revenue (Details)	9 Months Ended
	Sep. 30, 2021
Change In Contract With Customer Liability [Abstract]
Period for sales return	6 months

Revenue - Schedule of Rollforwa

Revenue - Schedule of Rollforward of Sales Return Liability (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Revenue Recognition [Abstract]
Beginning balance	$ 9,192	$ 8,116
Addition to reserve for sales activity	115,374	84,119
Actual returns	(110,996)	(82,110)
Change in estimate of sales returns	(1,265)	(46)
Ending balance	$ 12,305	$ 10,079

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of Convertible Note (Details) - Convertible Note $ in Thousands	Sep. 30, 2021USD ($)
Debt Instrument [Line Items]
Carrying Value	$ 46,657
Fair Value	$ 42,330

Balance Sheet Components (Inven

Balance Sheet Components (Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 2,669	$ 3,788
Work in progress	4,325	10,710
Finished goods	40,278	21,254
Finished goods - right of return	4,257	3,416
Inventory, net	$ 51,529	$ 39,168

Balance Sheet Components (PPE)

Balance Sheet Components (PPE) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 22,197		$ 22,197		$ 17,624
Less accumulated depreciation	(7,311)		(7,311)		(5,323)
Property and equipment, net	14,886		14,886		12,301
Depreciation expense	700	$ 900	2,200	$ 1,400
Leasehold improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,605		2,605		2,523
Manufacturing equipment and toolings
Property Plant And Equipment [Line Items]
Property and equipment, gross	9,832		9,832		8,529
Computer equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,637		1,637		2,522
Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,581		6,581		3,010
Furniture and fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,542		$ 1,542		$ 1,040

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Goodwill and intangible assets
Goodwill	$ 31,109	$ 31,109
Accumulated impairment losses	(21,907)	(21,907)
Goodwill, net	9,202	9,202
miraDry
Goodwill and intangible assets
Goodwill	7,629	7,629
Accumulated impairment losses	(7,629)	(7,629)
Plastic Surgery
Goodwill and intangible assets
Goodwill	23,480	23,480
Accumulated impairment losses	(14,278)	(14,278)
Goodwill, net	$ 9,202	$ 9,202

Balance Sheet Components - Comp

Balance Sheet Components - Components of Other Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Other intangible assets
Gross Carrying Amount	$ 16,443	$ 16,443
Accumulated Amortization	(8,422)	(7,506)
Intangible Assets, net	8,021	8,937
Indefinite-lived intangible assets	450	450
Trade name
Other intangible assets
Indefinite-lived intangible assets	$ 450	$ 450
Customer relationships
Other intangible assets
Average Amortization Period	10 years	10 years
Gross Carrying Amount	$ 4,940	$ 4,940
Accumulated Amortization	(4,132)	(3,856)
Intangible Assets, net	$ 808	$ 1,084
Trade name
Other intangible assets
Average Amortization Period	12 years	12 years
Gross Carrying Amount	$ 800	$ 800
Accumulated Amortization	(372)	(322)
Intangible Assets, net	$ 428	$ 478
Non-compete agreement
Other intangible assets
Average Amortization Period	2 years	2 years
Gross Carrying Amount	$ 80	$ 80
Accumulated Amortization	$ (80)	$ (80)
Regulatory approvals
Other intangible assets
Average Amortization Period	1 year	1 year
Gross Carrying Amount	$ 670	$ 670
Accumulated Amortization	$ (670)	$ (670)
Acquired FDA non-gel product approval
Other intangible assets
Average Amortization Period	11 years	11 years
Gross Carrying Amount	$ 1,713	$ 1,713
Accumulated Amortization	$ (1,713)	$ (1,713)
Manufacturing know-how
Other intangible assets
Average Amortization Period	19 years	19 years
Gross Carrying Amount	$ 8,240	$ 8,240
Accumulated Amortization	(1,455)	(865)
Intangible Assets, net	$ 6,785	$ 7,375

Balance Sheet Components (Goodw

Balance Sheet Components (Goodwill and Other Intangible Assets) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Other intangible assets
Amortization expense	$ 0.3	$ 0.3	$ 0.9	$ 1

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Future Estimated Amortization Expense (Details) $ in Thousands	Sep. 30, 2021USD ($)
Estimated amortization expense
2021	$ 305
2022	1,163
2023	1,092
2024	948
2025	805
Thereafter	3,708
Total amortization	$ 8,021

Balance Sheet Components (Accru

Balance Sheet Components (Accrued liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accrued and other current liabilities
Payroll and related expenses	$ 4,389	$ 3,003
Accrued severance	452	2,900
Accrued commissions	3,494	4,734
Accrued manufacturing	252	225
Deferred and contingent consideration, current portion	3,195	10,146
Audit, consulting and legal fees		48
Accrued sales and marketing expenses	96	300
Lease liabilities	1,618	1,588
Other	8,789	5,464
Total	$ 22,285	$ 28,408
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued and Other Current Liabilities	Accrued and Other Current Liabilities
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued and Other Current Liabilities	Accrued and Other Current Liabilities

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of rollforward of the accrued assurance-type warranties (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Balance Sheet Related Disclosures [Abstract]
Beginning Balance	$ 1,934	$ 1,397
Warranty costs incurred during the period	(270)	(83)
Changes in accrual related to warranties issued during the period	673	367
Changes in accrual related to pre-existing warranties	11	(5)
Ending Balance	$ 2,348	$ 1,676

Balance Sheet Components (Liabi

Balance Sheet Components (Liabilities measured at fair value) (Details)	9 Months Ended
	Sep. 30, 2021USD ($)
miraDry | Future Milestone Payments
Fair Value Measurements
Contingent consideration liability	$ 31,000
Estimated Dividend Yield
Fair Value Measurements
Measurement input	0
Measurement Input, Discount Rate | BIOCORNEUM | Future Royalty Payments
Fair Value Measurements
Fair value measurement discount rate	21.00%
Measurement Input, Discount Rate | miraDry | Future Milestone Payments
Fair Value Measurements
Fair value measurement discount rate	11.20%

Balance Sheet Components - Sc_4

Balance Sheet Components - Schedule of Company's Liabilities that are Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value Measurements
Fair value liability	$ 106	$ 33,596
Contingent Consideration Liability
Fair Value Measurements
Fair value liability	106	7,026
Derivative Liability
Fair Value Measurements
Fair value liability		26,570
Level 3
Fair Value Measurements
Fair value liability	106	33,596
Level 3 | Contingent Consideration Liability
Fair Value Measurements
Fair value liability	$ 106	7,026
Level 3 | Derivative Liability
Fair Value Measurements
Fair value liability		$ 26,570

Balance Sheet Components - Sc_5

Balance Sheet Components - Schedule of Aggregate Fair Values of Company's Liabilities for which Fair Value is Determined by Level 3 Inputs (Details) - Level 3 - Fair Value, Recurring $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Contingent Consideration Liability
Fair Value Measurements
Balance at beginning of the period	$ 7,026
Change in fair value	49
Settlements	(6,969)
Balance at the end of the period	106
Derivative Liability
Fair Value Measurements
Balance at beginning of the period	26,570
Change in fair value	14,460
Reclassification to equity	$ (41,030)

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Lessee Lease Description [Line Items]
Total operating lease cost	$ 326	$ 559	$ 1,315	$ 1,634
Finance lease cost
Total finance lease cost	22	25	67	62
Total lease cost	348	584	1,382	1,696
Inventory
Lessee Lease Description [Line Items]
Total operating lease cost	154	131	377	364
Finance lease cost
Amortization of right-of-use assets	12	12	35	24
Operating Expenses
Lessee Lease Description [Line Items]
Total operating lease cost	405	428	1,239	1,270
Sublease income	(233)		(301)
Finance lease cost
Amortization of right-of-use assets	8	10	26	31
Other Income (Expense), Net
Finance lease cost
Interest on lease liabilities	$ 2	$ 3	$ 6	$ 7

Leases (Details)

Leases (Details) - Sublease Agreement $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)
Lessee Lease Description [Line Items]
Initial sublease term	6 months
Subsequent option periods	24 months
Sublease Income	$ 0.5

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Operating and Finance Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflows from operating leases	$ 1,261	$ 1,337
Operating cash outflows from finance leases	56	61
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 572	1,242
Finance leases		$ 157

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related to Operating and Finance Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets And Liabilities Lessee [Abstract]
Operating lease right-of-use assets	$ 6,524	$ 7,176
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	us-gaap:OtherAssets	us-gaap:OtherAssets
Finance lease right-of-use assets	$ 97	$ 158
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	us-gaap:OtherAssets	us-gaap:OtherAssets
Total right-of use assets	$ 6,621	$ 7,334
Operating lease liabilities	$ 1,543	$ 1,504
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued and Other Current Liabilities	Accrued and Other Current Liabilities
Finance lease liabilities	$ 75	$ 84
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued and Other Current Liabilities	Accrued and Other Current Liabilities
Operating lease liabilities	$ 5,315	$ 5,946
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	sien:WarrantyReserveAndOtherLongTermLiabilitiesMember	sien:WarrantyReserveAndOtherLongTermLiabilitiesMember
Finance lease liabilities	$ 41	$ 77
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	sien:WarrantyReserveAndOtherLongTermLiabilitiesMember	sien:WarrantyReserveAndOtherLongTermLiabilitiesMember
Total lease liabilities	$ 6,974	$ 7,611
Weighted average remaining lease term (years)
Operating leases	4 years	5 years
Finance leases	2 years	2 years
Weighted average discount rate
Operating leases	8.09%	7.75%
Finance leases	6.48%	6.15%

Leases - Maturities of Operatin

Leases - Maturities of Operating and Finance Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Operating Lease Liabilities, Payments Due [Abstract]
Operating leases, Remainder of 2021	$ 564
Operating leases, 2022	2,035
Operating leases, 2023	2,085
Operating leases, 2024	1,629
Operating leases, 2025	704
Operating leases, 2026 and thereafter	1,221
Total operating lease payments	8,238
Less imputed interest, Operating leases	1,380
Total operating lease liabilities	6,858
Finance Lease Liabilities, Payments, Due [Abstract]
Finance leases, Remainder of 2021	27
Finance leases, 2022	58
Finance leases, 2023	33
Finance leases, 2024	4
Total finance lease payments	122
Less imputed interest, Finance leases	6
Total finance lease liabilities	116
Lessee Lease Liability Payments Due [Abstract]
Remainder of 2021	591
2022	2,093
2023	2,118
2024	1,633
2025	704
2026 and thereafter	1,221
Total lease payments	8,360
Less imputed interest	1,386
Total lease liabilities	$ 6,974	$ 7,611

Debt (Details)

Debt (Details)	Feb. 05, 2021USD ($)Tranche	Jul. 25, 2017	Sep. 30, 2021USD ($)shares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)shares	Sep. 30, 2020USD ($)	Jul. 01, 2022USD ($)	Sep. 28, 2021USD ($)$ / sharesshares	Jul. 01, 2021USD ($)	Dec. 31, 2020shares	May 11, 2020USD ($)
Line Of Credit Facility [Line Items]
Additional interest (as a percent)		5.00%
Common stock, shares issued | shares			58,129,589		58,129,589					50,712,151
Amortization of debt issuance costs and discounts					$ 2,632,000	$ 3,430,000
Gain on extinguishment of PPP loan					6,652,000
Paycheck Protection Program
Line Of Credit Facility [Line Items]
Gain on extinguishment of PPP loan			$ 6,700,000
Restated Term Loan Agreement
Line Of Credit Facility [Line Items]
Periodic commitment amount	$ 1,000,000										$ 15,000,000
Line of credit facility, remaining borrowing capacity	$ 15,000,000
Unfunded tranche revised number | Tranche	2
Debt instrument amendment fee	$ 750,000
Loan amount outstanding			16,000,000		16,000,000
Unamortized debt issuance costs			1,200,000		1,200,000
Restated Term Loan Agreement | Tranche 4
Line Of Credit Facility [Line Items]
Periodic commitment amount									$ 5,000,000
Restated Term Loan Agreement | Scenario Forecast | Tranche 5
Line Of Credit Facility [Line Items]
Periodic commitment amount							$ 5,000,000
Revolving Loan
Line Of Credit Facility [Line Items]
Loan amount outstanding			0		0
Revolving Loan | Other Assets
Line Of Credit Facility [Line Items]
Unamortized debt issuance costs			100,000		100,000
Term Loan and Revolving Loan
Line Of Credit Facility [Line Items]
Amortization of debt issuance costs			100,000	$ 200,000	400,000	700,000
Deerfield Facility Agreement
Line Of Credit Facility [Line Items]
Common stock, shares issued | shares								0
Derivative liability fair value								$ 41,000,000
Deerfield Facility Agreement | Convertible Note
Line Of Credit Facility [Line Items]
Unamortized debt discount and issuance costs			$ 13,300,000		$ 13,300,000
Debt instrument interest rate			12.00%		12.00%
Amortization of debt issuance costs and discounts			$ 800,000	$ 700,000	$ 2,200,000	$ 1,500,000
Deerfield Facility Agreement | Maximum
Line Of Credit Facility [Line Items]
Share price | $ / shares								$ 30
Deerfield Facility Agreement | Minimum
Line Of Credit Facility [Line Items]
Share price | $ / shares								$ 1.50

Debt (Schedule of Future Princi

Debt (Schedule of Future Principal Payments of Outstanding Debt) (Details) $ in Thousands	Sep. 30, 2021USD ($)
Debt Disclosure [Abstract]
2023	$ 10,105
2024	5,895
2025	60,000
Total	$ 76,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Stock other disclosures
Common and preferred stock, shares authorized	210,000,000	210,000,000
Common stock, shares authorized	200,000,000	200,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Stockholders' Equity (Warrants)

Stockholders' Equity (Warrants) (Details) - Oxford Finance, LLC - $ / shares	Jan. 17, 2013	Jun. 30, 2014	Sep. 30, 2021
Common Stock Warrants
Exercise price (in dollars per share)	$ 14.671	$ 14.671
Warrants outstanding			0
Tranche A, B and C loans
Common Stock Warrants
Warrant term	7 years
Percentage of term loan amounts	3.00%
Tranche D term loan
Common Stock Warrants
Warrant term		7 years
Percentage of term loan amounts		2.50%

Stockholders' Equity (Options)

Stockholders' Equity (Options) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future grants	1,253,615		1,253,615
Stock options
Number of options
Balance at the beginning of period (in shares)			1,959,501
Options exercised (in shares)			(36,363)
Options forfeited (in shares)			(138,859)
Balance at the end of the period (in shares)	1,784,279		1,784,279		1,959,501
Weighted average exercise price
Balance at the beginning of period (in dollars per share)			$ 4.79
Options exercised (in dollars per share)			3.99
Options forfeited (in dollars per share)			5.15
Balance at the end of period (in dollars per share)	$ 4.78		$ 4.78		$ 4.79
Additional information
Weighted average remaining contractual term			5 years 6 months		5 years 11 months 1 day
Stock-based compensation expense	$ 100,000	$ 0	$ 400,000	$ 0
Unrecognized compensation costs (in dollars)	$ 1,700,000		$ 1,700,000
2014 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future grants	1,860,554		1,860,554
Inducement Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future grants	638,710		638,710
Number of shares awarded			1,904,425
Grant period of stock awards			10 years
Number of additional years of requisite service period			3 years
Vesting period			1 year
Inducement Plan | On the first anniversary
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage			25.00%
Inducement Plan | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price of awards expressed as a percentage of fair value of shares on the date of grant			100.00%
Percentage of possible payouts of the target award			0.00%
Inducement Plan | Minimum | Individual options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage			25.00%
Inducement Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of possible payouts of the target award			100.00%
2007 Plan and 2014 Plan | Stock options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant period of stock awards			10 years
2007 Plan and 2014 Plan | Stock options | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price of awards expressed as a percentage of fair value of shares on the date of grant			100.00%
Percentage of voting power owned by shareholder	10.00%		10.00%
2007 Plan and 2014 Plan | Stock options | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price of awards expressed as a percentage of fair value of shares on the date of grant			110.00%

Stockholders' Equity (Restricte

Stockholders' Equity (Restricted Stock) (Details) - Restricted stock units - 2014 Plan - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Stockholders' Equity, other disclosures
Requisite service period, annually				3 years
Stock-based compensation expense	$ 2.1	$ 1.5	$ 7.3	$ 4.9
Unrecognized compensation costs (in dollars)	$ 11.1		$ 11.1
Weighted average period over which unrecognized compensation costs are expected to be recognized			2 years 18 days
Number of shares
Balance at beginning of the period			3,093,790
Granted			1,597,983
Vested			(1,174,753)
Forfeited			(392,728)
Balance at end of the period	3,124,292		3,124,292
Weighted average grant date fair value
Balance at beginning of the period			$ 6.97
Granted			7.38
Vested			6.99
Forfeited			6.98
Balance at end of the period	$ 7.17		$ 7.17

Stockholders' Equity (Stock Pur

Stockholders' Equity (Stock Purchase) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Oct. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future grants	1,253,615		1,253,615
2014 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase period of offering			6 months
Rate of purchase price of stock on fair value (as a percent)			85.00%
Purchases under the award			199,071
Weighted Average purchase price	$ 3.38		$ 3.38
Stock-based compensation expense	$ 100,000	$ 100,000	$ 400,000	$ 400,000
Incremental compensation cost			$ 0	$ 0
2014 Employee Stock Purchase Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Discount rate on the value of shares through payroll deductions (as a percent)			15.00%
Expiration period of each offering			27 months
Number of shares reserved for future issuance					255,500

Earnings (Loss) Per Share - Sch

Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator for continuing operations:
Income (loss) from continuing operations used in computing basic earnings (loss) per share	$ 28,503	$ (1,487)	$ (46,647)	$ (46,817)
Convertible note interest expense	1,392
Fair value adjustments to the derivative liability	(35,550)
Losses from continuing operations used in computing diluted loss per share	(5,655)	(1,487)	(46,647)	(46,817)
Numerator for discontinued operations:
Income (loss) from discontinued operations, net of income taxes	(93)	(4,334)	233	(21,893)
Income (loss) from discontinued operations used in computing basic and diluted earnings (loss) per share	(93)	(4,334)	233	(21,893)
Numerator for losses:
Net income (loss) used in computing basic earnings (loss) per share	28,410	(5,821)	(46,414)	(68,710)
Net loss used in computing diluted loss per share	$ (5,748)	$ (5,821)	$ (46,414)	$ (68,710)
Denominator:
Basic	58,005,784	50,394,858	56,680,594	50,155,623
Dilutive effect of the convertible note	14,634,146
Weighted average outstanding common shares for diluted loss per share	72,639,930	50,394,858	56,680,594	50,155,623
Basic earnings (loss) per share:
Continuing operations	$ 0.49	$ (0.03)	$ (0.82)	$ (0.93)
Discontinued operations	0	(0.09)	0	(0.44)
Basic earnings (loss) per share	0.49	(0.12)	(0.82)	(1.37)
Diluted earnings (loss) per share:
Continuing operations	(0.08)	(0.03)	(0.82)	(0.93)
Discontinued operations	0	(0.09)	0	(0.44)
Diluted earnings (loss) per share	$ (0.08)	$ (0.12)	$ (0.82)	$ (1.37)

Earnings (Loss) Per Share - S_2

Earnings (Loss) Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Potentially dilutive securities
Potentially dilutive securities	3,905,717	16,113,940	18,313,471	13,396,072
Stock issuable upon conversion of convertible note
Potentially dilutive securities
Potentially dilutive securities		14,634,146	14,634,146	11,002,710
Stock options to purchase common stock
Potentially dilutive securities
Potentially dilutive securities	1,582,901	34,308	1,629,493	862,278
Unvested RSUs
Potentially dilutive securities
Potentially dilutive securities	2,322,816	1,445,486	2,049,832	1,531,084

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Tax expense	$ 0	$ 0	$ 0	$ 0

Segment Information (Details)

Segment Information (Details)	9 Months Ended
	Sep. 30, 2021Segment
Segment Reporting [Abstract]
Number of reportable segments	1